Escolar Documentos
Profissional Documentos
Cultura Documentos
Journal Name
ARTICLE
1. Introduction
Azines are 2,3-diaza analogues of 1,3-butadiene and are
sometimes also referred as N—N linked diimines (C=N–N=C).1, 2 The Figure 1. Symmetrical azines (1,3) and unsymmetrical azines (2,4).
first example of azine is dimethylketazine which was synthesised by
Azines are receiving increasing attention for their
Curtius and Thun in 1891 from the reaction of two molecules of
biological, chemical and physical properties. This review deals
acetone with hydrazine.3 These compounds are conventionally with the alicyclic azines. These azines received much less
synthesised by the condensation of hydrazine with attention in chemistry due to two factors – (i) Predominance of
aldehydes/ketones.4 With the recent advances in the chemistry, the chemistry of hydrazones, which are tautomers of azines. (ii)
these compounds can also be synthesised by alternate routes.5 The Azines are highly basic and form salts very easily; in the
azines obtained from the condensation of aldehydes with hydrazine protonated state azines and hydrazones become equivalent.
are called as aldazines whereas the condensation products of Many azines were considered as hydrazones, the distinction
ketones with hydrazine are called as ketazines. 6 Azines are further between azines and hydrazones was rarely highlighted. For
classified as symmetrical azines 1 and unsymmetrical azines 2 (Figure example, the prominent drug belonging to azine class is
1). The azine 3 represents the example of symmetrical azine with N- Guanabenz (5)7 which was always considered as a
methylbenzothiazoline moiety attached to the azine framework guanylhydrazone derivative. Figure 2 shows two tautomeric
(C=N–N=C). The azines of such type have gained attention due to forms of Guanabenz (5A and 5B). The azine form 5B is more
their applications in redox chemistry. Structure 4 represents a special stable energetically (refer section 6).8, 9 Upon protonation, both
class of unsymmetrical azines which carry guanidine group.6 Among the tautomers yield the common species (5C) which closely
all the azines, type 4 azines are different with reference to their resembles the hydrazone framework. Hence, the scientific
community working on guanylhydrazones mostly considered
chemical reactivity. They are 1,1-diamino derivatives of azines (1,1-
1,1-diaminoazines as hydrazones rather than azines.8,9 This
diamino-2,3-diazabutadienes) and hence are highly basic, they
enticing representation lead to a decreased recognition of the
capture proton very easily and form salts.6
importance of azine class of compounds in chemistry.
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
Scheme 4. Formation of azines by reduction of 3-substituted 2-nitrosoimino-2,3- 2.4. Metal catalysed synthesis
dihydrobenzothiazole.20
Zhao et al.24 reported the formation of symmetrical
In 2016, Guo et al.21
developed a facile and efficient azines (23) which were produced by the copper catalyzed
method for the synthesis of structurally diverse azines (17) by homocoupling of oximes 22 (Scheme 7). The advantages
the reaction of the electrophilic reaction of 2,2,2- associated with this methodology include high functional group
trifluorodiazoethane (CF3CHN2) with the in situ generated N- tolerance, use of easily available oximes, good to excellent
heterocyclic carbenes from salt 16 under the basic conditions yields and mild reaction conditions. Another major advantage
(Scheme 5a). The authors suggested the notable features of of this method is to avoid the use of hazardous hydrazine
reaction are operational simplicity, mild reaction conditions, hydrate.
and easily accessible starting material.
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3
4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5
suggested that this electro-oxidation reaction is 2e- oxidation 3. Crystal structures of azines
process where KI acts as the source of iodide ions.
Azines contain two azomethine groups (C=N) which are
linked by a nitrogen-nitrogen single bond (N-N) and hence
structural preferences across the two double bonds in azines
are expected to be similar to that in 1,3-butadienes. The
conformation across 1,3-butadiene can be considered in two
ways, one is s-transoidal conformation and the other is s-
Scheme 16. Synthesis of azine by electrochemical oxidation.35 cisoidal gauche conformation.40 Similarly, in azines also two
conformations can be expected, i.e. s-transoidal and s-cisoidal
2.9. Miscellaneous methods gauche. In addition, across each of the C=N double bonds, E/Z
isomerisation can be expected. The crystal structure details of
Chen et al.36 reported a highly efficient and practical
selected 17 azines are provided in Table 1 (see Table SI-1 for a
protocol for the synthesis of azine 36, which involves the
comprehensive list of crystal structures of azines).
coupling of 3-ethyl-2-benzothiazolinone hydrazone (37) with 3-
The crystal structure data of various azines obtained
ethyl-2-iminobenzothiazoline bromide salt (38) using pyridine
from Cambridge Crystallographic Data Centre (CCDC) showed
as both solvent as well as base under refluxing condition for 12
that C-N-N-C torsional angle is between 110-180°.23, 41-96 It is
h (Scheme 17a).36 Sumran et al.37 reported the serendipitous,
interesting to note that s-trans conformation (C-N-N-C- dihedral
formation of azine 39 from the reaction of 3-hydrazonobutan-
angle ~180°) of azine is present in less than 50% of the crystal
2-one oxime (40) with aromatic aldehydes (Scheme 17b). The
structures reported and in the remaining cases, azines exhibit
CF3-substituted azines (41) have been synthesised by aza-Wittig
transoidal gauche conformation. The torsional angle data
reaction of aldehydes with trifluorodiazoethane. 38 The reaction
shown in Table 1 clearly establishes that s-transoidal gauche
proceeds via phosphazene intermediate P1, which would be
conformation is the preferred structure in most of the azines.
generated by the reaction of CF3CHN2 to PPh3. Further, the aza-
No structure with s-cisoidal gauche was noticed. The torsional
Wittig process of P1 with aldehydes gives azines (41) (Scheme
angle parameter was used to evaluate the extent/lack of
17c). The synthesis of symmetrical azines (42) was achieved
conjugation in azines, whereas, bond length parameters can be
with excellent yield by the treatment of acetonitrile-
used to understand the chemical bonding between the C=N and
H2O2/(NH4)2CO3 with aldehydes (Scheme 17d).39 This method
N–N bond in azines.
possesses the advantage of not using hydrazine. The authors
Most of the crystal structure analysis was carried out to
reported that the reaction will not proceed in the absence of
understand the stereochemistry and stereoelectronics of the
acetonitrile, as acetonitrile plays a very important role by
azines as they were found to be potential candidates for the
reacting with H2O2 under pH controlled condition to generate
nonlinear optic (NLO) materials. A few observations can be
peroxycarboximidic acid intermediate. The generated
made from the crystal structure data of azines as discussed
intermediate reacts rapidly with aldehyde in the presence of
below. In 3-Acetyl-4-(2-chlorophenyl)-4-hydroxy-2-
ammonium carbonate to produce azines.
methoxycrotonic acid lactone 43 (Entries 3 and 4, Table 1) two
conformers were noticed.42 Kurihara and co-workers42 reported
stereo chemical differences for two conformational isomers;
significant differences in the two isomers are due to deviation
across C-N-N-C torsional angle. The structure with 180°
torsional angle is red in colour and the structure with 114°
torsional angle is yellow in colour. In the crystal structure of the
opioid analgesic agent naltrexonazine 44 (entry 5, Table 1), the
deviation from s-trans arrangement is very significant
(118.6o).43 Similarly, the benzoxazepine 45 containing species
(entry 6, Table 1) shows strong deviation in torsional angle
(124.58o).45 Glaser and co-worker evaluated the stereo and
electronic character of acetophenone azine.48, 50, 53, 55 The halo
substituted systems showed strong deviation from s-trans
arrangement, for example, the diiodo system 46 (entry 7, Table
1) showed a torsional angle of 141.8°. The authors expected a
torsional angle value < 124° (but found 141.8o), this
phenomenon was attributed to the crystal packing factors. For
the dinitro compound 47 two conformers (entries 8 and 9, Table
Scheme 17. Miscellaneous methods of generating azine.
1) were reported, the differences in the two structures are
mostly due to torsional angle - the red isomer (~155°) and the
white isomer (~113°).
6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
1.268,
1. 1866599 2019 Polymorphism 179.76
1.323
1.392
1.273,
2. 1866600 2019 Polymorphism 173.01
1.332
1.389
Stereoelectronic,
139916 stereochemistry,
7. 1999 141.82 1.288 1.39.6
crystal packing for
NLO property
Crystal structure
8. 984383 2018 155.22 1.281, 1.279 1.375
determination
Crystal structure
9. 984384 2018 113.37 1.286, 1.288 1.390
determination
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 7
To study the
coordination mode of
14. 770436 2011 180.00 1.300 1.412
azines (Chances for
catalysis)
To study the
coordination mode of
15. 770437 2011 180.00 1.295 1.410
azines (Chances for
catalysis)
158.17
Coordination
16. 1183096 1989 chemistry of azine 1.282, 1.260 1.410
with metal (palladium)
Charge transfer
1.322,
17. 695874 2009 complex and radical 180.00 1.354
1.312
cation of azine
Charge transfer
18. 695875 2009 complex and radical 180.00 1.286 1.410
cation of azine
Synthesis of azine
19. 1520662 2017 179.33 1.320, 1.278 1.372
from NHC precursor
8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 9
10 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 11
cases. On the other hand in case of naloxonazine-estrone azine, degradation study was carried out which suggests that isomer II
configurationally pure anti-anti isomer was observed as it was degrades in the range of 463-483 K whereas isomer I degrades
synthesised from pure anti-estrone hydrazone.112 in the range of 435-483 K. Computational analysis using Semi-
Lipkowska et al.43 carried out the synthesis and X-Ray empirical CNDO/2 method indicated that the twisted isomer is
crystallographic studies to understand the configuration and energetically more stable by ~15 kJ/mol. This conformational
conformation of naltrexonazine. Under acid conditions, from isomerism indicates that the C=N-N=C conjugation is very weak.
hydrazine hydrochloride and naltrexone hydrochloride in
refluxing methanol they isolated only one isomer in 93% yield
(labelled it as anti-anti isomer, Figure 7). The crystal structure
of this isomer could be obtained by recrystallisation in isopropyl
alcohol. As discussed in section 3, this compound exhibits s-
transoidal gauche conformation (118o) across the C=N-N=C
framework. The authors also reported the generation of
another isomer in neutral medium when the compound was
synthesised using naltrexone (free base) with anhydrous
hydrazine in methanol, which was recognized on the basis of
NMR (labelled syn-anti isomer). Upon heating (with time), the Figure 8. The two conformers of azine of 3-Acetyl-4-(2-chlorophenyl)-4-hydroxy-
2- methoxycrotonic acid lactone (43) observed in the solid state.
authors reported the conversion of the second isomer to the
major isomer.43 The conformational isomerism observed by Tighadouini
et al. 113 in 4-nitroacetophenonazine (47 entries 8 and 9, Table
1) also deserves elaborate discussion. The reaction between
hydrazine hydrate and p-nitroacetophenone yields the red
crystalline species, which upon thermal treatment in methanol
undergoes thermal isomerisation to produce the white
crystalline solid. The coloured species was with C=N-N=C
torsional angle 155o is close to being s-trans isomer and the
white species with 113o torsional angle can be considered as the
Figure 7. The crystal structure of anti-anti isomer of naltrexonazine (44), showing
the quite twisted conformation across the C=N-N=C central unit.43 s-transoidal gauche conformer. The 3D structures of these two
conformers are shown in Figure 9 (CCDC-Mercury). The
5.2 Conformational isomerism in azines interconversion rate between the two conformers is 85:15
Conformational isomers are possible in azines by (red:white) under methanol refluxing condition. The authors
rotation across N–N single bond. The conformation of aromatic suggested that the red isomer is semi-flexible due to the
azines is controlled by a chain of four atoms: C=N–N=C. When presence of conjugation.
the two groups are arranged anti to each other across -N–N-
plane with C=N–N=C dihedral angle of 180°, the azines exhibit
s-trans conformation and when the two groups are arranged on
the same side of -N–N- plane with C=N–N=C dihedral angle of 0°
then the azines exhibit s-cis conformation. When the two
groups are arranged anti to each other across -N–N- plane with
C=N–N=C dihedral angle of 180°, the azines exhibit s-trans
conformation and when the two groups are arranged on the
same side of -N–N- plane with C=N–N=C dihedral angle of 0°
then the azines exhibit s-cis conformation. Many crystal
structures of azines have been reported (Table 1) to understand
the stereochemistry and stereoelectronics. From these studies
Figure 9. Conformational isomers of (1E,2E)-bis[1-(4-nitrophenyl)ethylidene]
it may be concluded that all the conjugation stopper azines exist hydrazine observed in single crystal XRD.
in s-transoidal gauche conformation with torsional angle across
C=N–N=C is in the range of 115-165° whereas other azines exist The matrix isolation infrared spectroscopic study and
in s-trans conformation with the torsional angle across C=N-N=C quantum chemical calculations have been carried out on 2'-
is ~180°, in such azines the conjugation was found to be hydroxyacetophenone azine (71, Figure 10) by Grzegorzek et
maximal (Table 1). al.114 Density functional Theory (DFT) B3LYP/6-311++G(2d,2p)
As pointed out in section 3, Ishida et al.42 observed the calculations suggested the presence of two conformers for the
conformational isomers of 3-Acetyl-4-(2-chlorophenyl)-4- lowest energy E/E configuration of 2'-hydroxyacetophenone
hydroxy-2-methoxycrotonic acid lactone (43, Table 1, entry 3 azine. The conformers differ in the value of a C=N-N=C dihedral
and 4); Figure 8 shows the 3D structures of the two isomers angle – 180° for a planar s-trans conformer and 155° for a non-
(generated from the CCDC-Mercury software). The thermal planar conformer.
12 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 13
14 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
polymorphism in azines were reported, the same are presented inversion in space groups P21/n for Form Ia and P21/c for Form
in this section. Ib, respectively. The crystal packing analysis suggests that the
Glaser and co-workers, in 1994, reported the molecules in Form Ia are linked into chains by aromatic -
polymorphism and conformational analysis of two rotational stacking interactions whereas this aromatic - stacking
isomers of methyl (para-tolyl) ketone azines using ab initio interactions are absent in Form Ib and instead a C—H (arene)
calculation and X-ray crystal structures analysis 77.47 Two hydrogen bond is present.
isomers co-crystalized in two monoclinic racemic modification.
Both the rotamers assume the (E,E) configuration in which the
large groups attached to the C=N bonds are trans but they differ
in their conformation across N-N single bond. In the case of
rotamer A, molecule exhibits s-trans conformation (C=N-N=C
torsional angle 180o), while rotamer B exhibits s-gauche
conformation (C=N-N=C torsional angle 142.8°) (Figure 14). The
energy difference between the two rotamers is 0.36 kcal/mol Figure 16. 3D structure of (E,E)-1,4-Bis(2-nitrophenyl)-2,3-diaza-1,3-butadiene
(79).
according to RHF/6-31G*//RHF/3-21G level of quantum
chemical analysis. The authors concluded that “the small Wang and co-workers,124 in 2019, reported the
differences in packing interactions in polymorphous crystals temperature controlling polymorphism and polymorphic
suffice to overcome the intrinsic trans preference”. interconversion in sublimation crystallisation of 5-Methoxy-
salicylaldhyde azine 80 (Figure 17). They demonstrated use of
“an in-air sublimation method for strategically preparation of
two polymorphic crystal forms by controlling sublimation
temperature”. The azine (yellowish powder) was prepared by
the reaction of 2-hydroxy-5-methoxybenzaldehyde with
hydrazine hydrate at 80 °C for 5 h. This yellow powder was
subjected to sublimation using a device consisting of an electric
Figure 14. 3D structures of two rotamers of Methyl (para-Tolyl)ketone azine (77).
hot jacket and a micro sublimator. The polymorph A (exhibiting
orange yellow fluorescence) was obtained as rod like crystals
Amadei et al.,122 in 1998, reported structures of two
when the temperature in the micro sublimator reached 170 °C
polymorphic forms of phenyl 2-pyridyl azine 78. The suitable
and polymorph B (exhibiting weak red fluorescence) was
crystals for the single crystal X-ray diffraction study were
obtained as lamellar crystals at 220 °C (Figure 17).124
developed in methanol by a slow evaporation method. The
white crystals (Form A) and yellow crystals (Form B) were
obtained in 60:40 ratio with an overall yield of 85%. Both forms
are associated with the same Z,Z isomeric state. The authors
reported that “the main crystallographic differences between
the two compounds are” due to the torsional angle across C=N-
N=C framework – 123.4° for Form A (gauche) and 180° for Form
B (s-trans). The orientation of the pyridyl ring also is different in
these two forms. Also, the N-N bond distance is shorter (1.38 Å)
in Form A, in comparision to that 1.41 Å in Form B (Figure 15).
The computational analysis showed that the s-trans conformer
is more stable than gauche conformer by ~2 kcal/mol.
Figure 17. A) 2D structure of 5-Methoxy-salicylaldhyde Azine; B) Fluorescence
microscope images of polymorph 80A and polymorph 80B in the solid state under
UV light excitation (. reproduced with permission American Chemical Society).
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 15
polymorphic forms- Form I i.e. E-isomer (5_E, Entry 1, Table 1) considered to carry the L→N coordination interactions. It is
and Form II i.e. Z-isomer (5_Z, Entry 2, Table 1). The Form I interesting to note that these structural features are known to
crystals adopts block shape whereas Form II adopts rod shape present in many drugs and leads.136
(Figure 18).97 The crystal packing analysis suggested that the
molecules in Form I are arranged in zigzag form whereas in Form
II molecules are arranged in lamellar packing. The differences in
the intermolecular hydrogen bonding and π-stacking
interactions were analysed by quantum chemical analysis and
Hirshfeld surfaces of these two forms.
Figure 19. A) Compounds with central main group elements in their low oxidation
state; B) Triphenyl phosphenazine (84A) and its suggested mesomeric form with
P→N dative bond (84B).
16 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
moiety. HOMO and HOMO-1 represent the molecular orbitals 9. Redox system in azines
with -type and -type lone pair character.143 Himmel and co- Violenes are violet coloured radical species with the
workers studied urea azines (52, 53, 86-88, Figure 20) to general formula given in Figure 21. They are stable radical ions
understand their redox property and coordination chemistry which derive their stability due to the distribution of odd
with metals.89 They also explored the possibility of CN number of electrons over an even number of atoms arranged in
coordination bond in this class of molecules using experimental a chain. The π-electron delocalisation of a single electron across
and quantum chemical studies. DFT calculations were carried a chain of conjugated double bond provides the intense colour.
out to estimate the enthalpies and Gibbs free energies for the
decomposition of azine into dinitrogen and carbene. The data
suggested the presence of C→N dative bond between
dinitrogen and two carbene atoms. However, the data obtained
Figure 21. General structure of violene with two resonating forms.
from vibrational spectroscopy suggested that the electronic
properties of urea azines are comparable to those of Azaviolenes are also violet coloured species which carry
formaldazine, H2C=N-N=CH2. Therefore, authors concluded that N-N bonds embedded in conjugated radical cation systems (92-
the decomposition energies are indicative of the stability of the 97, Figure 22). Thus azines in their radical cation state are
carbene decomposition products and since the electronic azaviolenes. The redox chemistry of these species was
properties are comparable to those of formaldazine, urea azines extensively explored. However, the bonding characteristic and
52, 53, 86-88 cannot be adequately described in terms of dative electron delocalisation were not thoroughly explored. 147 The
bonding.89 reduced form of the azine (3 Reduced) is reported to undergo
In view of the limited studies on the chemical bonding electron transfer process (Scheme 23). 148-151
across C=N vs. C→N bonds in azines (Figure 19), more studies
are required to explore this concept in detail. Unsymmetrical
azines are gaining importance in organic chemistry, material
chemistry, and medicinal chemistry. In this context, we became
interested in unsymmetrical azines possessing N-heterocycles
such as benzothiazole (89A) due to the importance of this
scaffold in medicinal chemistry. Considering the case of
triphenylphosphenazene (84A) which possess two PN dative
bonds due to the electron donating nature of
Figure 22. Examples of Azaviolenes.
triphenylphosphine, similar (NHC)N bonding situation in
azine 89A between C=N can be expected (Figure 19).
The reduced form of 3 undergoes single electron
Exploration of properties and applications of unsymmetrical
transfer to form radical cation species (3 semiquinone) and
azines is in underway in our laboratory.
upon second electron transfer, forms dicationic species (3
oxidised, Scheme 23). The rate of formation of these species is
determined by oxidation potential calculated from cyclic
voltammetry.148
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 17
Himmel and co-workers in 2015 reported various urea Figure 24. The chemical structure of ABTS, ABTS radical cation (ABTS+) and ABTS dication
(ABTS++). 154
azines/bisguanidines as strong electron donors with the help of
cyclic voltammetry (CV).89 The authors suggested the electron
donating ability of compounds 52, 53, 86-88 (Figure 20) using 10. Applications of azines in medicinal chemistry
CV which showed these compounds can be reversibly oxidized Azines have been investigated for their diverse therapeutic
in two well separated one-electron steps and thus can behave activities. Though only one of them, Guanabenz (5) is a
as strong reducing agents (Figure 23). They also compared the marketed drug (anti-hypertensive agent), several azine
adiabatic ionisation energies (I1) of these species with the I1 of containing compounds exhibited therapeutic potential.155
TDAE (tetrakis(dimethyl ethylamino)ethylene) using Figures 24 and 25 list a few important azines, which were
computational methods. The observed adiabatic ionisation considered for therapeutic applications. The diaminoazines are
energy values are in the order of 88 < 53 < 52, the lower highly basic and hence under physiological condition tend to
ionisation energy of 94 may be attributed towards exist in the protonated state.
intramolecular hydrogen bonding. Compound 53 was also
oxidised with TCNQ which gave the radical salt 53_TCNQ.89
Figure 23. A schematic diagram showing the redox chemistry of urea azines
(reproduced with permission from Wiley-VCH).
2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic Acid)152
(ABTS) acts as a substrate for the enzymatic assay of peroxidase
enzymes. In ABTS/H2O2 peroxidase system, ABTS acts as a
reducing agent that converts the active state (enzyme after
oxidation by H2O2) of the enzyme to its native state (Figure 24).
The colour of ABTS is pale greenish with the max of 340 nm,
whereas ABTS radical cation (highly stable) is green-blue colour
with the max values of 414, 645, 734, and 815 nm. This
oxidation process was utilized indirectly to either calculate the Figure 25. The 2D structures of several medicinally important 1,1-diaminoazines.
amount of hydrogen peroxide produced in the enzymatic
environment or to study the reaction kinetics of hydrogen These diaminoazines in their protonated state have been
peroxide-producing enzyme153 Based on a similar concept, ABTS reported to be useful as lead compounds (Figure 25) in drug
18 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
discovery, the important examples are – the antihypertensive major side-effects. For example, 5 was reported to possess an
agent (5) carrying 2,6-dichloro with 1,1-diamino unit,156 the antiparasitic activity (Toxoplasma gondii) against acute and
trypanocidal agent (99) containing two azine units attached to latent toxoplasmosis. 5 was also found to significantly reduce
pyridine,157 the antibacterial compound (100) with biphenyl the number of brain cysts in chronically infected mice which
ring,158 the antimalarial agent (101) derived from suggests its ability to reduce tissue cysts in the brain. 1675 was
benzophenone,159 the antiseptic known as ambazone (102), the tested in vivo in animal models for the treatment of prion-based
anticoagulant thrombin inhibitor (103) with aryl sulfonyl group diseases (transmissible neurodegenerative disorder) by Blondel
in the side chain,160 and the anticancer species (104-106).161 et al.168 It was found to be active in vivo against yeast and
The non-diaminoazines based lead compounds were mammalian prion. Experiments revealed that the removing of
also reported and a few of them are shown in Figure 26.69 chlorine or replacement of chlorine in Guanabenz with fluorine
Though they are also sufficiently basic, they are reported to be or bromide results in the loss of activity in yeast-based and
showing their therapeutic action as neutral molecules. MovS6-based assays. In contrast, addition of extra chloride in
Naphtho[2,1-b]furan based azines (107) as antibacterial agents, the phenyl ring in 5 increased its activity.168 Voisset et al., in
unsymmetrical azines derived from naphthaldazines (108) are 2014,169 suggested that 5 is also active against both yeast and
antifungal agents,162 bisisatin azine as an anticancer agent mammalian prions but in an independent manner without
(109),163 monoterpene indole alkaloid azine derivatives (110) as affecting α2-adrenergic receptor. Authors performed the
MDR reversal agents.164 Kalinowski et al. reported the structure activity relationship study by modulating 5–5i and 5j
identification of an azine disulfide dimer (111) as an (Figure 27) were found to possess antiprion activity totally
antiproliferative agent (it also exhibits iron chelator property).69 devoid of 2-adrenoceptor agonistic activity.169
Urbanczyk-Lipkowska et al.43 reported the X-ray crystal
structure and biological evaluation of naltrexonazine (44) as
opioid antagonist. Similarly, 14-hydroxy dihydroxymorphinone
azine is also reported as opioid antagonist. 165
Figure 26. Biologically active azines, along with their suggested therapeutic
applications. Figure 28. Anti-microbial azines.
Guanabenz (5, (E)-2,6-dichlorophenyl-1,1-diamino-2,3- Jayabharathi et al.,171 in 2007, reported the synthesis and
diazabuta-1,3-diene) is an orally active central 2-adrenoceptor antimicrobial activity of N(1)-arylidene-N(2)-cis-2,6-
agonist used for the treatment of hypertension. The diphenyltetrahydrothiopyran-4-one azine derivatives. The
antihypertensive action of Guanabenz is attributed to result synthesised compounds were evaluated against Bacillus subtilis,
from the reduction in sympathetic outflow from the brain to the Streptococcus faecalis, Pseudomonas aeruginosa, Escherichia
peripheral circulatory system.166 Many researchers are coli, and Staphylococcus aureus and antifungal activity
exploring the possibility ‘repurposing’ Guanabenz for different against Candida-51, Candida-6, niger, Aspergillus
biological activities as it is in clinical use for many years without and Aspergillus flavus. The compounds 114 and 115 (Figure 28)
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 19
exerted improved in vitro antibacterial and antifungal activity P. aeruginosa PAO1 and 118 reported to possess the binding
against all the tested strains. A semi-empirical quantum chemical affinity (KD) of 5.7 µM and MIC of 52.3 µg/mL. Further, the in
analysis was performed to validate the stereochemical cellulo HemO inhibitory activity of compounds were carried out
observations obtained through NMR studies. It was found that to access the ability of compounds to inhibit the activity of
the chair conformation with equatorial orientation of phenyl HemO. The compound 118 was found to inhibit HemO activity
groups is the energetically preferred arrangement of the at effective concentration of 11.3 µM measured by biliverdin-
thiopyran ring. dependent IFP1.4 fluorescence. The compound binds to the
In 2013, Liang et al. reported the in vitro and in vivo novel binding site which was proposed using in silico studies and
antitumor activity of bis-Schiff base derivatives of Isatin. 172 A further supported by hydrogen exchange mass spectrometry
series of 18 compounds were synthesised, interestingly more (HXMS) and saturation transfer difference (STD) NMR.175
than half of the compounds were found to be cytotoxic in five
different human cell lines (HeLa, SGC-7901, HepG2, U251 and
A549). Among the promising compounds, bisisatin azine 109
was found to be the most potent against HepG2 cell line with
the IC50 value of ~4.23 µM (Figure 26). The authors have also
studied the effect of 109 on the HepS-bearing mice at a dose of Figure 30. Diaminoazines as hemeoxygenase of Pseudomonas aeruginosa
inhibitor.
40mg/kg. The mechanistic investigation revealed that the
compound 109 arrest the cell cycle in G2/M phase by down Subedi et al. in 2017, reported azines as anti-
regulating the expression of cyclin B1 and cdc 2. 172 neuroinfammatory agents.2 A series of thirteen azines were
Our lab was involved in the design and synthesis of a synthesised from aldehydes and biologically evaluated in LPS-
series of benzothiazole based unsymmetrical azines as quorum activated BV-2 microglial cells. The compounds were found to
sensing (QS) inhibitors targeting LasR.173 The compounds were affect the LPS-mediated neuroinflammation in microglia and
designed based on the reported pharmacophore model174 neuronal apoptosis through inhibiting MAPK signalling
which suggested that the ligands should possess a polar region pathway. Compound 119 (Figure 31) was found to exhibit anti-
linking the aromatic box and hydrophobic box to interact with neuroinflammatory activity with the IC 50 value of 12.47 µM by
LasR. In the designed molecules, the azine group is acting as a protecting neurons from microglia-mediated neurotoxicity.
polar linker joining the benzothiazole (hydrophobic box) and Moreover, it also possesses neuroprotective effect by inhibiting
aromatic ring (aromatic box). The designed compounds were LPS-mediated necrosis and apoptosis, the neuroprotective
synthesised by using one pot method which involves the effect was further supported by FACS analysis. 2
reaction of substituted aldehyde, 3-Methyl-2-
(methylthio)benzo[d]thiazol-3-ium salt and hydrazine hydrate.
The synthesised compounds were preliminarily tested in
Chromobacterium violaceum for evaluating their potential to
inhibit CviR receptor based QS signals. Out of 25 evaluated Figure 31. The structure of most active azine reported as anti-neuroinfammatory
agent.
compounds, 2 compounds (116 and 117) were found to inhibit
>50 % violacein inhibition at 200 µM (Figure 29). The
11. Azines as substrates in the generation of
compounds were further found to inhibit the QS-mediated GFP
heterocycles
signals when tested for LasR receptor based QS using PlasB-
Apart from the application of azines in redox and
gfp(ASV) biomonitor strain of Pseudomonas aeruginosa.
medicinal chemistry, they have been used as a substrate for the
Interestingly, the two active compounds also inhibited biofilm
construction of heterocycles. The reactions of dienophilic
formation at 50 µM concentration.173
compounds with azines represent a valuable enlargement to
synthetic heterocyclic chemistry. Azines have been reported to
undergo criss-cross cycloaddition reaction.176 Azines obtained
from aromatic aldehydes or from hexafluoroacetone are
reported to undergo criss-cross addition with 2 moles of a
dienophile to form 1,5-diazabicyclo[3.3.0]octane derivatives. 10
The chemistry of azines with dienophiles was discussed
extensively in a review published in 1976 by Wagner-Jauregg.10
Safari and Gandomi-Ravandi also discussed a few interesting
cycloaddition reactions of azines. Hence in this section, our
Figure 29. a) Design strategy using suggested pharmacophore; b) active quorum
main focus is to cover reactions of azines which involve the
sensing inhibitors. construction of medicinally important heterocycles such as
oxadiazoles,177 triazoles,178 diazepines,179 pyrazoles180 and
In 2016, Heinzl et al. reported the diaminoazines pyridines.181
(iminoguanidines) as allosteric inhibitors of iron regulated In 1967, Gillis and Lamontagne reported the formation of
Hemeoxygenase of Pseudomonas aeruginosa (Figure 30).175 A oxadiazole by the oxidation of aldazines (120) with lead
series of diaminoazines were synthesised and evaluated against
20 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 21
22 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 23
24 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 25
26 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 27
violet from pale yellow and the absorption band shifted from
445 to 575 nm.238
In 2013, Ray et al. reported the synthesis of p-N,N-
diethylaminobenzaldazine (157, Figure 42) and the
spectroscopic properties (PDEAB) were analysed using steady
state absorption and fluorescence measurement. The analysis
suggested that the PDEAB forms intermolecular hydrogen bond
with protic solvents which indeed results in the turn-on
fluorescence. The authors suggested that this study helps in
detecting the traces of polar solvent in aprotic medium. 239
Figure 42. Salicyladehyde (155, 157) and julolidine based azines (156) as
chemosensors.
28 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
anisotropic crystalline structure, push-pull effects as well as optical azines, the electron delocalisation properties, the charge
properties of azine based material, thus providing the excellent distribution properties, isomerism (E/Z, tautomerism, and
bridge between the synthesis, electronic, structure and NLO conformational isomerism), reactivity, bonding situation as well
properties of several azine derivatives. 56, 252 as material characteristics (e.g. NLO). The structural features of
Facchetti et al. reported azinium-(π-bridge)-pyrrole these compounds provide large variations, thus, providing
NLO- phores (165, Figure 46) properties and the effect of opportunity for exploring the influence of substituents on the
modulating the heterocyclic acceptors on chromophoric and electronic characteristics. A few of these azine derivatives were
self-assembled (SA) thin layer properties were studied. 254 In the shown to carry important therapeutic applications such as anti-
designed possess, pyrrol-2-yl ring act as primary donor groups hypertensive, anti-parasitic, anti-microbial and anti-cancer.
and -deficient azinium acceptor. The authors suggest that the Guanabenz, an anti-hypertensive drug has been repurposed for
chromophore and SA properties are mainly influenced by the anti-parasitic and anti-prion activity. Many innovative structure
nature of -deficient azinium acceptor.254 Similarly, 1,3-dithiol- frameworks with the help of azine constructs are being
2-ylidene donor-acceptor chromophores containing an azine generated towards the synthesis of N-heterocycles such as
spacer was reported by Moreno-ManÄas.253 Valverde et al. also triazoles, diazepines, pyrazoles, isoquinolines, dihydropyridines
reported the potential application of unsymmetrical azines in and oxadiazoles. The interesting physical characteristics such as
the development of NLO material.94 structural, magnetic and optical properties of azines make them
potential candidates for the design of MOF, COF, conducting
material, sensing material, energetic material, liquid crystals
and NLOs. Apart from these applications, the azine metal
complexes have also been reported extensively in literature.
The contents of this article while indicating the
versatility of azines, lead to many intriguing queries e.g., the
variation exhibited by the structures of azines, leave many
questions unanswered specially regarding conjugation across
the azine framework. The effect of substituents on the
Figure 46. The figure represents the example of azinium-(π-bridge)-pyrrole NLO-
phores. conjugation across C=N-N=C is currently the topic of concern for
the scientific community which needs to be unraveled. The
Recently, Custodio et al. reported the supramolecular approach azine-hydrazone tautomerism in this class of molecules has
to predict the nonlinear optics potential of (7E, 8E)-2-(3- been well studied but there is need to study triple tautomerism
methoxy-4-hydroxy-17-benzylidene)-1-(4-Nitrobenzyliden n)- (azine-azo-hydrazone) using theoretical as well as experimental
hydrazine (166, NMZ, an asymmetrical azine, Figure 47). The methods. Similarly, polymorphism in azines have also been
optical dipole moment (𝜇), the linear polarisation (𝛼) and the reported up to a limited extent and there is scope to explore.
first (𝛽) and second (𝛾) hyperpolarizability were investigated The redox chemistry and the associated electron exchange
which suggest NMZ carries properties of good nonlinear optical characteristics and their influence on the chemical bonding in
material.250 their system needs to be explored. Molecular switching is a
topic of contemporary interest because of their application in
the design of electronics and optical memory devices. The
azines can be used to design the molecular switch material as it
carries the electro- or photo- switchable subunits and thus
exploration is required in this direction. The scope of 1,1-
diaminoazines should be considered for the design of material
Figure 47. Structure of NMZ. such as MOF and COF. The scope of azines as substrate needs
to be considered for the synthesis of heterocycles such as
Apart from the above applications other related application of imidazopyridines, triazines, etc. More importantly, 1,1-
azines are in in liquid crystal, organic field-effect transistor diaminoazine class of molecules can be explored as a substrate
(OFET),257 organic light emitting diodes (OLEDs),262 for Biginelli reaction. Apart from these, limited literature on the
photovoltaic,259 film transistors263 etc. azines as directing group needs to be scrutinized. The limited
literature on this specific class of azines needs to be expanded.
14. Conclusions and Future Perspectives These opportunities shall have a great influence on the
Azines are versatile class of compounds with wide range therapeutic, organic as well as material characteristics of
of applications. In this review, it was established that there are chemicals carrying azine moiety.
several innovative methods of synthesising azine class of
compounds. One of the recent methods involve the formation Conflicts of interest
of azines from the reaction of alcohol with hydrazine hydrate in
“There are no conflicts to declare”.
presence of catalyst such as ruthenium pincer complex, Ni(II)
complex of 2,6-bis(phenylazo)pyridine. Quantum chemical
studies can be efficiently used to obtain the 3D-structures of the
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 29
1. J. Safari and S. Gandomi-Ravandi, RSC Adv., 2014, 4, 46224- 27. C. Sánchez-Sánchez, J. I. Martínez, N. Ruiz del Arbol, P.
46249. Ruffieux, R. Fasel, M. F. López, P. L. de Andres, J. Á. Martín-
2. L. Subedi, O. W. Kwon, C. Pak, G. Lee, K. Lee, H. Kim and S. Gago, Angew. Chem., 2018, 130, 8718-8722.
Y. Kim, BMC neurosci., 2017, 18, 82. 28. J. Lasri, M. M. Aly, N. E. Eltayeb and B. A. Babgi, J. Mol.
3. T. Curtius and K. Thun, J. Prakt. Chem., 1891, 44, 161-186. Struct., 2018, 1164, 1-8.
4. J. P. Schirmann and P. Bourdauducq, Ullmann's 29. H. Nanjundaswamy and M. Pasha, Synth. Commun., 2007,
Encyclopedia of Industrial Chemistry, 2000. 37, 3417-3420.
5. J. O. Bauer, G. Leitus, Y. Ben-David and D. Milstein, ACS 30. B. Lee, S. H. Kang, D. Kang, K. H. Lee, J. Cho, W. Nam, O. H.
Catal., 2016, 6, 8415-8419. Han and N. H. Hur, Chem. Commun., 2011, 47, 11219-
6. G. Moss, P. Smith and D. Tavernier, Pure Appl. Chem., 1995, 11221.
67, 1307-1375. 31. B. Lee, P. Kang, K. H. Lee, J. Cho, W. Nam, W. K. Lee and N.
7. S. Diamant, I. Agranat, A. Goldblum, S. Cohen and D. Atlas, H. Hur, Tetrahedron Lett., 2013, 54, 1384-1388.
Biochem. Pharmacol., 1985, 34, 491-498. 32. V. Arun and K. Sankaran, Int. Lett. Chem., Phys. Astron.,
8. A. Ramakrishnan, S. S. Chourasiya and P. V. Bharatam, RSC 2015, 58, 137.
Adv., 2015, 5, 55938-55947. 33. S. Simeonov, V. Kurteva and R. Bontchev, Bulg. Chem.
9. S. S. Chourasiya, D. Kathuria, S. S. Nikam, A. Ramakrishnan, Commun., 2008, 40, 409-417.
S. Khullar, S. K. Mandal, A. K. Chakraborti and P. V. 34. A. A. Aly, A. A. Hassan, A. B. Brown, M. A. Ibrahim and E.-S.
Bharatam, J. Org. Chem., 2016, 81, 7574-7583. S. AbdAl-Latif, J. Sulfur Chem., 2017, 38, 11-17.
10. T. Wagner-Jauregg, Synthesis, 1976, 1976, 349-373. 35. M. Okimoto, T. Yoshida, M. Hoshi, K. Hattori, M. Komata,
11. S. Upadyaya, P. Bhagavath and D. Sunil, J. Mol. Liq., 2018, K. Tomozawa and T. Chiba, Synth. Commun., 2008, 38,
269, 354-370 3320-3328.
12. L. Zhao, M. Hermann, N. Holzmann and G. Frenking, Coord. 36. J. Chen, X. Zhou and T. Yuan, Synth. Commun., 2014, 44,
Chem. Rev., 2017, 344, 163-204. 3630-3636.
13. E. Kuznetsova, V. Bogolyubskii, L. Bogolyubskaya, T. 37. G. Sumran, R. Aggarwal, M. Hooda, D. Sanz and R. M.
Stepanova and S. Zhuravlev, Chem. Heterocycl. Compd., Claramunt, Synth. Commun., 2018, 48, 439-446.
1967, 3, 659-661. 38. F. G. Zhang, N. Lv, Y. Zheng and J. A. Ma, Chin. J. Chem.,
14. D. Guerin, D. Lorcy, R. Carlier, S. Los and L. Piekara-Sady, J. 2018, 36, 723-730.
Solid State Chem., 2002, 168, 590-596. 39. A. R. M. Ebrahimlo and K. Nazarlou, Org. Commun., 2018,
15. Q. Sha and Y. Wei, Tetrahedron, 2013, 69, 3829-3835. 11, 111.
16. Z.-G. Luo, P. Liu, Y.-Y. Fang, X.-M. Xu, C.-T. Feng, Z. Li, X.-M. 40. A. J. P. Devaquet, R. E. Townshend and W. J. Hehre, J. Am.
Zhang and J. He, Res. Chem. Intermed., 2017, 43, 1139- Chem. Soc., 1976, 98, 4068-4076.
1148. 41. Meerssche, G. Duchene and H. Viehe, Acta Crystallogr.,
17. C. J. Abelt and J. M. Pleier, J. Am. Chem. Soc., 1989, 111, Sect. B: Struct. Crystallogr. Cryst. Chem. 1977, 33, 1263-
1795-1799. 1266.
18. J. M. Hopkins, M. Bowdridge, K. N. Robertson, T. S. 42. T. Ishida, M. Inoue, K. Nasu and T. Kurihara, Acta
Cameron, H. A. Jenkins and J. A. Clyburne, J. Org. Chem., Crystallogr., Sect. C: Cryst. Struct. Commun., 1983, 39, 470-
2001, 66, 5713-5716. 473.
19. M. Regitz, G. Weise, B. Lenz, U. Förster, K. Urgast and G. 43. Z. Urbanczyk-Lipkowska, A. Lipkowski, M. Etter, E. Hahn, G.
Maas, Bull. Soc. Chim. Belg., 1985, 94, 499-520. Pasternak and P. S. Portoghese, J. Med. Chem., 1987, 30,
20. K.-y. Akiba, T. Kawamura, M. Ochiumi and N. Inamoto, Bull. 1489-1494.
Chem. Soc. Jpn., 1976, 49, 1913-1916. 44. C.-F. Chang, C.-H. Cheng, C.-C. Wang and S.-L. Wang, Acta
21. R. Guo, Y. Zheng and J.-A. Ma, Org. Lett., 2016, 18, 4170- Crystallogr., Sect. C: Cryst. Struct. Commun., 1989, 45,
4173. 1705-1707.
22. L. Zhang, X. H. Meng, P. Liu, J. Chen and Y. L. Zhao, Eur. J. 45. E. E. Schweizer, Z. Cao, J. E. Hayes and A. L. Rheingold, The
Org. Chem., 2017, 2017, 6137-6145. J. Org. Chem., 1990, 55, 1687-1690.
23. S. Wei, S. Li, C. Chen, Z. He, X. Du, L. Wang, C. Zhang, Q. 46. R. Glaser, G. S. Chen and C. L. Barnes, J. Org. Chem., 1993,
Wang and L. Pu, , Adv. Synth. Catal., 2017, 359, 1825-1830. 58, 7446-7455.
24. M.-N. Zhao, H. Liang, Z.-H. Ren and Z.-H. Guan, Synthesis, 47. G. S. Chen, M. Anthamatten, C. L. Barnes and R. Glaser,
2012, 44, 1501-1506. Angew. Chem., Int. Ed. Engl.,1994, 33, 1081-1084.
25. M. Chakraborty, D. Sengupta, T. Saha and S. Goswami, J. 48. G. S. Chen, M. Anthamatten, C. L. Barnes and R. Glaser, J.
Org. Chem., 2018, 83, 7771-7778. Org. Chem., 1994, 59, 4336-4340.
26. B. A. Shiekh, D. Kaur and S. K. Godara, Catal. Commun., 49. I. Mutikainen, H. Elo and P. Tilus, Z. Naturforsch. B Chem.
2019, 124, 19-23. Sci., 1993, 48, 1821-1827.
30 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
50. G. ShiahuyáChen, J. Chem. Soc., Perkin Trans. 2, 1995, 75. R. Archana, R. Anbazhagan, K. Sankaran, A. Thiruvalluvar
1449-1458. and R. Butcher, Acta Crystallogr., Sect. E: Struct. Rep.
51. A. Osborne, M. W. Da Silva, M. Hursthouse, K. Malik, G. Online, 2010, 66, o345-o345.
Opromolla and P. Zanello, J. Organomet. Chem., 1996, 516, 76. L.-L. Han, J.-H. Shi, D.-P. Yan and S. W. Ng, Acta Crystallogr.,
167-176. Sect. E: Struct. Rep. Online, 2010, 66, o561-o561.
52. M. Lewis, C. L. Barnes, B. A. Hathaway and R. Glaser, Acta 77. R. Archana, R. Anbazhagan, K. Sankaran, A. Thiruvalluvar
Crystallogr., Sect. C: Cryst. Struct. Commun., 1999, 55, 975- and R. Butcher, Acta Crystallogr., Sect. E: Struct. Rep.
978. Online, 2010, 66, o1586-o1586.
53. M. Lewis, C. L. Barnes and R. Glaser, J. Chem. Crystallogr., 78. V. Pintos, A. Cuevas, S. Onetto, G. Seoane, P. Denis, J.
1999, 29, 1043-1048. Gancheff, R. Faccio, A. Mombrú and C. Kremer, J. Mol.
54. D. Sanz, M. Alejandra Ponce, R. María Claramunt, C. Struct., 2010, 963, 9-15.
Fernández‐Castaño, C. Foces‐Foces and J. Elguero, J. Phys. 79. Q. Ali, I. Anis, M. Raza Shah and S. W. Ng, Acta Crystallogr.,
Org. Chem., 1999, 12, 455-469. Sect. E: Struct. Rep. Online, 2011, 67, o531-o531.
55. M. Lewis, C. L. Barnes and R. Glaser, Acta Crystallogr., Sect. 80. B. Lee, K. H. Lee, J. Cho, W. Nam and N. H. Hur, Org. Lett.,
C: Cryst. Struct. Commun., 2000, 56, 393-396. 2011, 13, 6386-6389.
56. M. Lewis, C. L. Barnes and R. Glaser, J. Chem. Crystallogr., 81. M. Reinmuth, C. Neuhäuser, P. Walter, M. Enders, E. Kaifer
2000, 30, 489-496. and H. J. Himmel, Eur. J. Inorg. Chem., 2011, 2011, 83-90.
57. S. U. Son, K. H. Park, I. G. Jung, Y. K. Chung and M. S. Lah, 82. A. Peters, H. Herrmann, M. Magg, E. Kaifer and H. J.
Organometallics, 2002, 21, 5366-5372. Himmel, Eur. J. Inorg. Chem., 2012, 2012, 1620-1631.
58. R. Van Deun, T. N. Parac-Vogt, K. Van Hecke, L. Van 83. W. Imhof and J. Wunderle, Acta Crystallogr., Sect. E: Struct.
Meervelt, K. Binnemans, D. Guillon and B. Donnio, J. Mater. Rep. Online, 2012, 68, o2741-o2741.
Chem., 2003, 13, 1639-1645. 84. W. N. A. Al-Mehana, R. Yahya, F. Sonsudin, I. N. A. Al-
59. C. Glidewell, J. N. Low, J. M. Skakle and J. L. Wardell, Acta Mehana and K. M. Lo, Acta Crystallogr., Sect. E: Struct. Rep.
Crystallogr., Sect. C: Cryst. Struct. Commun., 2004, 60, o38- Online, 2012, 68, o2990-o2990.
o40. 85. V. Davydov, V. Sokol, N. Rychagina, R. Linko, M. Ryabov, Y.
60. A. Şengül, N. Karadayı and O. Büyükgüngör, Acta V. Shklyaev and V. Sergienko, Russ. J. Inorg. Chem., 2009,
Crystallogr., Sect. C: Cryst. Struct. Commun., 2004, 60, 54, 893-905.
o507-o508. 86. N. Sajitha, M. Sithambaresan and M. P. Kurup, Acta
61. D. D. Choytun, L. D. Langlois, T. P. Johansson, C. L. Crystallogr., Sect. E: Struct. Rep. Online, 2013, 69, o1755-
Macdonald, G. W. Leach, N. Weinberg and J. A. Clyburne, o1755.
Chem. Commun., 2004, 1842-1843. 87. M. Akita, M. Takahashi, K. Kobayashi, N. Hayashi and H.
62. M. Mijanuddin, W. Sheldrick, H. Mayer-Figge, M. Ali and N. Tukada, J. Mol. Struct., 2013, 1034, 346-353.
Chattopadhyay, J. Mol. Struct., 2004, 693, 161-165. 88. A. Bouchama, M. Yahiaoui, C. Chiter, Z. Setifi and J.
63. C. G. Hamaker, O. Maryashina and D. P. Halbach, Acta Simpson, Acta Crystallogr., Sect. E: Crystallogr. Commun.,
Crystallogr., Sect. E: Struct. Rep. Online, 2006, 62, o802- 2015, 71, 35-37.
o803. 89. H. Herrmann, M. Reinmuth, S. Wiesner, O. Hübner, E.
64. X. Li, H. Sun, F. Yu, U. Flörke and H.-F. Klein, Kaifer, H. Wadepohl and H. J. Himmel, Eur. J. Inorg. Chem.,
Organometallics, 2006, 25, 4695-4697. 2015, 2015, 2345-2361.
65. T. Nakano, H. Kakuda, Y. Mori and M. Shiro, Acta 90. J. Gómez, A. H. Klahn, M. Fuentealba, D. Sierra, C. Olea-
Crystallogr., Sect. C: Cryst. Struct. Commun., 2006, 62, Azar and M. E. Medina, Inorg. Chem. Commun., 2015, 61,
o331-o332. 204-206.
66. L. Busetto, F. Marchetti, S. Zacchini and V. Zanotti, 91. J. Lasri, N. E. Eltayeb and A. I. Ismail, J. Mol. Struct., 2016,
Organometallics, 2007, 26, 3577-3584. 1121, 35-45.
67. Z.-W. Fu, Acta Crystallogr., Sect. E: Struct. Rep. Online, 92. G. Albertin, S. Antoniutti, M. Bortoluzzi, J. Castro, F. Sibilla
2007, 63, o2993-o2993. and E. Trave, New J. Chem., 2017, 41, 12976-12988.
68. C. Villiers, P. Thuéry and M. Ephritikhine, Chem. Commun., 93. S. Adhikari, W. Kaminsky and M. R. Kollipara, J. Organomet.
2007, 2832-2834. Chem., 2017, 848, 95-103.
69. D. S. Kalinowski, P. C. Sharpe, P. V. Bernhardt and D. R. 94. C. Valverde, W. F. Vaz, J. M. Custodio, V. S. Duarte, P. S.
Richardson, J. Med. Chem., 2007, 50, 6212-6225. Carvalho-Jr, A. S. Figueredo, G. L. de Aquino, B. Baseia and
70. M. R. Rizal, H. M. Ali and S. W. Ng, Acta Crystallogr., Sect. H. B. Napolitano, New J. Chem., 2017, 41, 11361-11371.
E: Struct. Rep. Online, 2008, 64, o555-o555. 95. S. Tighadouini, S. Radi, L. Toupet, M. Sirajuddin, T. B.
71. F.-F. Cen, C. Xu, Z.-Q. Wang, L. Cheng and Y.-Q. Zhang, Acta Hadda, M. Akkurt, I. Warad, Y. N. Mabkhot and S. Ali, J.
Crystallogr., Sect. E: Struct. Rep. Online, 2009, 65, o3051- Chem. Sci., 2015, 127, 2211-2216.
o3051. 96. R. d. L. Nathasha, T. C. Noguiera, A. C. Pinheiro, M. V. de
72. L. Yang, Y. Xie, J. Zou, J. Jia and X. Hong, Acta Crystallogr., Souza, L. R. Gomes, J. N. Low, J. L. Wardell and S. M.
Sect. E: Struct. Rep. Online, 2009, 65, m1017-m1017. Wardell, Cryst. Mater., 2018, 233, 135-143.
73. Z. Časar, I. Leban, A. Majcen-le Marechal, L. Piekara-Sady 97. D. Kathuria, S. S. Chourasiya, A. A. Wani, M. Singh, S. C.
and D. Lorcy, Acta Chim. Slov., 2009, 12, 1057-1065. Sahoo and P. V. Bharatam, Cryst. Growth Des., 2019, 19,
74. S. Gatard, S. Blanchard, B. Schollhorn, P. Gouzerh, A. Proust 3183-3191.
and K. Boubekeur, Chem. Eur. J., 2010, 16, 8390-8399. 98. R. Glaser, G. S. Chen, M. Anthamatten and C. L. Barnes, J.
Chem. Soc., Perkin Trans 2, 1995, DOI:
10.1039/P29950001449, 1449-1458.
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 31
99. M. Lewis and R. Glaser, J. Org. Chem., 2002, 67, 1441-1447. 129. S. Bhatia, C. Bagul, Y. Kasetti, D. S. Patel and P. V. Bharatam,
100. H. Lund, Acta Chem. Scand, 1959, 13, 4. J. Phys. Chem. A, 2012, 116, 9071-9079.
101. J. Ludvı ́k, F. Riedl, F. Liška and P. Zuman, J. Electroanal. 130. S. Bhatia, J. Malkhede Y. and P.V. Bharatam, J. Comput.
Chem., 1998, 457, 177-190. Chem., 2013, 34, 1577-1588.
102. P. Zuman and J. Ludvı ́k, Tetrahedron Lett., 2000, 41, 7851- 131. S. Bhatia and P. V. Bharatam, J. Org. Chem., 2014, 79, 4852-
7853. 4862.
103. V. A. Sauro and M. S. Workentin, J. Org. Chem., 2001, 66, 132. T. Singh and P. V. Bharatam, J. Comput. Chem., 2019,
831-838. https://doi.org/10.1002/jcc.25872.
104. C. McLoughlin, J. A. C. Clyburne and N. Weinberg, J. Mater. 133. N. Patel, R. Sood and P. V. Bharatam, Chem. Rev., 2018,
Chem., 2007, 17, 4304-4308. 118, 8770-8785.
105. W. A. Barlow, G. R. Davies, E. P. Goodings, R. L. Hand, G. 134. N. Patel, B. Falke, P. V. Bharatam, Theor. Chem. Acc., 2018,
Owen and M. Rhodes, Mol. Cryst. Liq. Cryst., 1976, 33, 123- 137, 34.
148. 135. H. Bruns, M. Patil, J. Carreras, A. Vázquez, W. Thiel, R.
106. H. Mailer and S. Laskos Jr, Google Patents, 1980. Goddard and M. Alcarazo, Angew. Chem. Int. Ed., 2010, 49,
107. M. S. Silva Artur, L. M. Silva Vera, M. Claramunt Rosa, S. 3680-3683.
María Dolores, B. Ferraro Marta, F. Reviriego, I. Alkorta and 136. D. Kathuria, M. Arfeen, A. A. Bankar and P. V. Bharatam, J.
J. Elguero, Magn. Reson. Chem., 2013, 51, 530-540. Chem. Sci., 2016, 128, 1607-1614.
108. K. Appenroth, M. Reichenbächer and R. Paetzold, J. 137. R. Kinjo, B. Donnadieu, M. A. Celik, G. Frenking and G.
Photochem., 1980, 14, 51-60. Bertrand, Science, 2011, 333, 610-613.
109. K. Appenroth, M. Reichenbächer and R. Paetzold, J. 138. M. A. Celik, R. Sure, S. Klein, R. Kinjo, G. Bertrand and G.
Photochem. 1984, 24, 65-70. Frenking, Chem.Eur. J, 2012, 18, 5676-5692.
110. K. Appenroth, E. Birckner and M. Reichenbächer, J. 139. Y. Xiong, S. Yao, S. Inoue, J. D. Epping and M. Driess, Angew
Photochem. 1987, 37, 117-124. Chem., 2013, 125, 7287-7291.
111. K. Appenroth, M. Reichenbächer and R. Paetzold, 140. Y. Xiong, S. Yao, S. Inoue, J. D. Epping and M. Driess, Angew.
Tetrahedron, 1981, 37, 569-573. Chem. Int. Ed., 2013, 52, 7147-7150.
112. V. M. Kolb and D. H. Hua, J. Org. Chem., 1984, 49, 3824- 141. Y. Xiong, S. Yao, G. Tan, S. Inoue and M. Driess, J. Am. Chem.
3828. Soc., 2013, 135, 5004-5007.
113. S. Tighadouini, S. Radi, L. Toupet, M. Sirajuddin, T. B. 142. Y. Wang, Y. Xie, P. Wei, R. B. King, H. F. Schaefer, P. v. R.
Hadda, M. Akkurt, I. Warad, Y. N. Mabkhot and S. Ali, J. Schleyer and G. H. Robinson, J. Am. Chem. Soc., 2008, 130,
Chem. Sci., 2015, 127, 2211-2216. 14970-14971.
114. J. Grzegorzek, Z. Mielke and A. Filarowski, J. Mol. Struct., 143. N. Holzmann, D. Dange, C. Jones and G. Frenking, Angew.
2010, 976, 371-376. Chem. Int. Ed., 2013, 52, 3004-3008.
115. V. V. Davydov, V. I. Sokol, N. A. Polyanskaya, R. V. Linko, M. 144. M. Y. Abraham, Y. Wang, Y. Xie, R. J. Gilliard, P. Wei, B. J.
A. Ryabov and V. S. Sergienko, Crystallogr. Rep., 2012, 57, Vaccaro, M. K. Johnson, H. F. Schaefer, P. v. R. Schleyer and
227-234. G. H. Robinson, J. Am. Chem. Soc., 2013, 135, 2486-2488.
116. H. Loghmani-Khouzani, A. Minaeifar and R. Gawinecki, J. 145. D. J. D. Wilson, S. A. Couchman and J. L. Dutton, Inorg.
Mol. Struct., 2013, 1032, 138-146. Chem., 2012, 51, 7657-7668.
117. G. Giorgi, F. Ponticelli, L. Savini, L. Chiasserini and C. 146. R. Appel and R. Schöllhorn, Angew Chem., 2006, 76, 991-
Pellerano, J. Chem. Soc., Perkin Trans. 2, 2000, 2259-2264. 992.
118. O. Büyükgüngör, M. Odabaşoğlu, A. Vijesh and H. 147. S. Hünig, Pure Appl. Chem., 1967, 15, 109-122.
Yathirajan, Acta Crystallogr., Sect. E: Struct. Rep. Online, 148. S. Hünig, G. Kieβlich, F. Linhart and H. Schlaf, Justus Liebigs
2007, 63, o4084-o4085. Ann. Chem., 1971, 752, 182-195.
119. R. Rogers, ACS Publications, 2003. 149. S. Hünig, H. Balli, H. Conrad and A. Schott, Justus Liebigs
120. G. R. Desiraju, Cryst. Growth Des., 2008, 8, 3-5. Ann. Chem., 1964, 676, 52-65.
121. D. Singhal and W. Curatolo, Adv. Drug Delivery Rev., 2004, 150. S. HIinig, H. BaIli, H. Conrad and A. Schott, Ann Chem, 1964,
56, 335-347. 676, 36-51.
122. E. Amadei, M. Carcelli, S. Ianelli, P. Cozzini, P. Pelagatti and 151. S. Hünig, H. Balli, H. Conrad and A. Schott, Justus Liebigs
C. Pelizzi, J. Chem. Soc., Dalton Trans., 1998, 1025-1030. Annalen der Chemie, 1964, 676, 36-51.
123. C. Glidewell, J. N. Low, J. M. Skakle and J. L. Wardell, Acta 152. H. Gallati, J. Clin. Chem. Clin. Biochem., 1979, 17, 1-7.
Crystallogr. Sect. B: Struct. Sci., 2006, 62, 666-675. 153. R. Apak, E. Capanoglu and F. Shahidi, Measurement of
124. S. Shen, G. Xia, Z. Jiang, Q. Shao, W. Shan and H. Wang, Antioxidant Activity and Capacity: Recent Trends and
Cryst. Growth Des., 2018, 19, 320-327. Applications, John Wiley & Sons, 2017.
125. P. V. Bharatam, M. Arfeen, N. Patel, P. Jain, S. Bhatia, A. K. 154. R. van den Berg, G. R. Haenen, H. van den Berg and A. Bast,
Chakraborti, S. Khullar, V. Gupta and S. K. Mandal, Chem. Food Chemistry, 1999, 66, 511-517.
Eur. J., 2016, 22, 1088-1096. 155. B. Holmes, R. Brogden, R. Heel, T. Speight and G. Avery,
126. N. Patel, M. Arfeen, R. Sood, S. Khullar, A. K. Chakraborti, Drugs, 1983, 26, 212-229.
S. K. Mandal and P. V. Bharatam, Chem. Eur. J., 2018 24, 156. T. George, C. L. Kaul, R. S. Grewal and D. V. Mehta, J. Med.
6418-6425. Chem., 1971, 14, 909-913.
127. D. S. Patel and P. V. Bharatam, Chem. Commun., 2009, 157. R. J. Sundberg, D. J. Dahlhausen, G. Manikumar, B.
1064-1066. Mavunkel, A. Biswas, V. Srinivasan, H. A. Musallam, W. A.
128. D. S. Patel and P. V. Bharatam, J. Phys. Chem. A, 2011, 115, Reid and A. L. Ager, J. Med. Chem., 1990, 33, 298-307.
7645-7655.
32 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
158. G. Cavallini, E. Massarani, D. Nardi, L. Mauri and P. 184. Z. Györgydeák and W. Holzer, Heterocycles, 1998, 48,
Mantegazza, J. Med. Pharmaceut. Chem., 1961, 4, 177-182. 1395-1406.
159. F. A. French, J. R. DoAmaral, E. J. Blanz and D. A. French, J. 185. J. Boyle and M. Grundon, Chem. Commun., 1967, 1137-
Med. Chem., 1971, 14, 862-866. 1138.
160. N. Desideri, I. Sestili, S. Manarini, C. Cerletti and M. L. Stein, 186. B. Szőcs, É. Bokor, K. E. Szabó, A. Kiss-Szikszai, M. Toth and
Eur. J. Med. Chem., 1991, 26, 455-460. L. Somsák, RSC Adv., 2015, 5, 43620-43629.
161. A. Andreani, M. Rambaldi, A. Leoni, A. Locatelli, R. Bossa, 187. D. Kathuria, P. Gupta, S. S. Chourasiya, S. C. Sahoo, U.
A. Fraccari, I. Galatulas and G. Salvatore, J. Med. Chem., Beifuss, A. K. Chakraborti and P. V. Bharatam, Org. Biomol.
1996, 39, 2852-2855. Chem., 2019, 17, 4129-4138.
162. V. B. Kurteva, S. P. Simeonov and M. Stoilova-Disheva, 188. W. Han, G. Zhang, G. Li and H. Huang, Org. Lett., 2014, 16,
Pharmacol. Pharm., 2011, 2, 1. 3532-3535.
163. C. Liang, J. Xia, D. Lei, X. Li, Q. Yao and J. Gao, European J. 189. D. S. Deshmukh, P. A. Yadav and B. M. Bhanage, Org.
Med. Chem., 2014, 74, 742-750. Biomol. Chem., 2019, 17, 3489-3496.
164. A. Paterna, R. Khonkarn, S. Mulhovo, A. Moreno, P. 190. D. Kathuria, S. S. Chourasiya, S. K. Mandal, A. K.
Madeira Girio, H. Baubichon-Cortay, P. Falson and M.-J. U. Chakraborti, U. Beifuss and P. V. Bharatam, Tetrahedron,
Ferreira, Bioorg. Med. Chem., 2018, 26, 421-434. 2018, 74, 2857-2864.
165. E. F. Hahn, M. Carroll-Buatti and G. W. Pasternak, J. 191. M. Kallitsakis, E. Loukopoulos, A. Abdul‐Sada, G. J. Tizzard,
Neurosci., 1982, 2, 572-576. S. J. Coles, G. E. Kostakis and I. N. Lykakis, Adv. Synth. Catal.,
166. D. T. NASH, J. Clin. Pharmacol., 1973, 13, 416-421. 2017, 359, 138-145.
167. I. Benmerzouga, L. A. Checkley, M. T. Ferdig, G. 192. S. Chittaboina, F. Xie and Q. Wang, Tetrahedron Lett.,
Arrizabalaga, R. C. Wek and W. J. Sullivan, Antimicrob. 2005, 46, 2331-2336.
Agents Chemother., 2015, 59, 6939-6945. 193. D. Dönnecke, J. Wunderle and W. Imhof, J. Organomet.
168. D. Tribouillard-Tanvier, V. Béringue, N. Desban, F. Gug, S. Chem., 2004, 689, 585-594.
Bach, C. Voisset, H. Galons, H. Laude, D. Vilette and M. 194. Y.-G. Lim and B. T. Koo, Tetrahedron Lett., 2005, 46, 385-
Blondel, PloS One, 2008, 3, e1981. 388.
169. P. h. Nguyen, H. Hammoud, S. Halliez, Y. Pang, J. Evrard, M. 195. J. Wen, A. Wu, M. Wang and J. Zhu, J. Org. Chem., 2015, 80,
Schmitt, N. Oumata, J.-J. Bourguignon, S. Sanyal, V. 10457-10463.
Beringue, M. Blondel, F. Bihel and C. Voisset, ACS Chem. 196. Y. Yu, C. Kuai, R. Chauvin, N. Tian, S. Ma and X. Cui, J. Org.
Neurosci., 2014, 5, 1075-1082. Chem., 2017, 82, 8611-8616.
170. M. N. Ristić, N. S. Radulović, B. R. Dekić, V. S. Dekić, N. R. 197. W. B. Euler and C. R. Hauer, Solid State Commun., 1984, 51,
Ristić and Z. Stojanović-Radić, Chem. Biodiversity, 2019, 16, 473-476.
e1800486. 198. W. B. Euler, Chem. Mater., 1996, 8, 554-557.
171. J. Jayabharathi, V. Thanikachalam, A. Thangamani and M. 199. C. R. Hauer, G. S. King, E. L. McCool, W. B. Euler, J. D. Ferrara
Padmavathy, Med. Chem. Res., 2007, 16, 266-279. and W. J. Youngs, J. Am. Chem. Soc., 1987, 109, 5760-5765.
172. C. Liang, J. Xia, D. Lei, X. Li, Q. Yao and J. Gao, Eur. J. Med. 200. B. Chaloner-Gill, C. J. Cheer, J. E. Roberts and W. B. Euler,
Chem., 2014, 74, 742-750. Macromolecules, 1990, 23, 4597-4603.
173. S. S. Chourasiya, D. Kathuria, S. Singh, V. C. Sonawane, A. K. 201. B. Chaloner-Gill, W. B. Euler, P. D. Mumbauer and J. E.
Chakraborti and P. V. Bharatam, RSC Adv., 2015, 5, 80027- Roberts, J. Am. Chem. Soc., 1991, 113, 6831-6834.
80038. 202. D. S. Dudis, A. T. Yeates, D. Kost, D. A. Smith and J.
174. S. Skovstrup, S. T. Le Quement, T. Hansen, T. H. Jakobsen, Medrano, J. Am. Chem. Soc., 1993, 115, 8770-8774.
M. Harmsen, T. Tolker‐Nielsen, T. E. Nielsen, M. Givskov 203. C. McLoughlin, J. A. Clyburne and N. Weinberg, J. Mater.
and O. Taboureau, ChemMedChem, 2013, 8, 157-163. Chem., 2007, 17, 4304-4308.
175. G. A. Heinzl, W. Huang, W. Yu, B. J. Giardina, Y. Zhou, A. D. 204. C. Chakravarty, B. Mandal and P. Sarkar, J. Phys. Chem. C.,
MacKerell Jr, A. Wilks and F. Xue, J. Med. Chem., 2016, 59, 2018, 122, 3245-3255.
6929-6942. 205. S. Dalapati, S. Jin, J. Gao, Y. Xu, A. Nagai and D. Jiang, J. Am.
176. C. Kelley, L. A. Mercando, M. R. Terry, N. Lugan, G. L. Chem. Soc., 2013, 135, 17310-17313.
Geoffroy, Z. Xu and A. L. Rheingold, Angew. Chem., 1992, 206. Y. Ma, H. Li, S. Peng and L. Wang, Anal. Chem., 2012, 84,
104, 1066-1068. 8415-8421.
177. J. Boström, A. Hogner, A. Llinàs, E. Wellner and A. T. 207. S. B. Alahakoon, C. M. Thompson, A. X. Nguyen, G.
Plowright, J. Med. Chem., 2012, 55, 1817-1830. Occhialini, G. T. McCandless and R. A. Smaldone, Chem.
178. C. H. Zhou and Y. Wang, Curr. Med. Chem., 2012, 19, 239- Commun., 2016, 52, 2843-2845.
280. 208. Z. Li, X. Feng, Y. Zou, Y. Zhang, H. Xia, X. Liu and Y. Mu,
179. J. Barluenga, M. J. Iglesias and V. Gotor, J. Chem. Soc., Chem. Commun., 2014, 50, 13825-13828.
Chem. Commun., 1987, 209. V. S. Vyas, F. Haase, L. Stegbauer, G. Savasci, F. Podjaski, C.
180. M. J. Naim, O. Alam, F. Nawaz, M. J. Alam and P. Alam, J. Ochsenfeld and B. V. Lotsch, Nat. Commun., 2015, 6, 8508.
Pharm. BioAllied Sci., 2016, 8, 2-17. 210. L. Stegbauer, M. W. Hahn, A. Jentys, G. k. Savasci, C.
181. A. A. Altaf, A. Shahzad, Z. Gul, N. Rasool, A. Badshah, B. Lal Ochsenfeld, J. A. Lercher and B. V. Lotsch, Chem. Mater.,
and E. Khan, J. Drug Des. Med. Chem., 2015, 1, 1-11. 2015, 27, 7874-7881.
182. B. T. Gillis and M. P. LaMontagne, J. Org. Chem., 1967, 32, 211. M. Shan, B. Seoane, E. Rozhko, A. Dikhtiarenko, G. Clet, F.
3318-3320. Kapteijn and J. Gascon, Chem. Eur. J., 2016, 22, 14467-
183. Z. Györgydeák, W. Holzer, R. Kunz and A. Linden, Monatsh. 14470.
Chem, 1995, 126, 733-746.
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 33
212. O. M. Yaghi, M. O'keeffe, N. W. Ockwig, H. K. Chae, M. 240. Y. Liu, Q. Teng, J. Hu, R. Sun and H. Zhang, Sens. Actuators,
Eddaoudi and J. Kim, Nature, 2003, 423, 705. B, 2016, 234, 680-690.
213. M. Eddaoudi, J. Kim, N. Rosi, D. Vodak, J. Wachter, M. 241. J.-H. Hu, Y. Sun, J. Qi, Q. Li and T.-B. Wei, Spectrochim. Acta,
O'keeffe and O. M. Yaghi, Science, 2002, 295, 469-472. Part A, 2017, 175, 125-133.
214. M. Y. Masoomi and A. Morsali, Coord. Chem. Rev., 2012, 242. Y. Sun, J.-H. Hu, J. Qi and J.-B. Li, Spectrochim. Acta, Part A,
256, 2921-2943 . 2016, 167, 101-105.
215. M. P. Suh, H. J. Park, T. K. Prasad and D.-W. Lim, Chem. Rev., 243. B. Yu, C.-Y. Li, Y.-X. Sun, H.-R. Jia, J.-Q. Guo and J. Li,
2011, 112, 782-835. Spectrochim. Acta, Part A, 2017, 184, 249-254.
216. J.-R. Li, R. J. Kuppler and H.-C. Zhou, Chem. Soc. Rev., 2009, 244. P.-X. Pei, J.-H. Hu, Y. Chen, Y. Sun and J. Qi, Spectrochim.
38, 1477-1504. Acta A, 2017, 181, 131-136.
217. D. K. Maity, B. Bhattacharya, R. Mondal and D. Ghoshal, 245. A. Ghosh, S. Adhikari, S. Ta, A. Banik, T. K. Dangar, S. K.
CrystEngComm, 2014, 16, 8896-8909. Mukhopadhyay, J . S. Matalobos, P. Brandão, V. Félix and
218. E. Tahmasebi, M. Y. Masoomi, Y. Yamini and A. Morsali, D. Das, Dalton Trans., 2016, 45, 19491-19499.
Inorg. Chem., 2014, 54, 425-433. 246. A. Iwan and D. Sek, Prog. Polym. Sci., 2011, 36, 1277-1325.
219. M. Y. Masoomi, K. C. Stylianou, A. Morsali, P. Retailleau and 247. H.-J. Niu, Y.-D. Huang, X.-D. Bai and X. Li, Mater. Lett., 2004,
D. Maspoch, Cryst. Growth Des., 2014, 14, 2092-2096. 58, 2979-2983.
220. M. Y. Masoomi, S. Beheshti and A. Morsali, J. Mater. Chem. 248. L.-Y. Kong, Z.-W. Li, T.-a. Okamura, G.-H. Ma, Q. Chu, H.-F.
A, 2014, 2, 16863-16866. Zhu, S.-H. Tang, W.-Y. Sun and N. Ueyama, Chem. Phys.
221. A. R. Abbasi, M. Yousefshahi and A. Azadbakht, Colloids lett., 2005, 416, 176-181.
Surf. A 2016, 498, 58-65. 249. A. L. Briseno, S. C. Mannsfeld, C. Reese, J. M. Hancock, Y.
222. G.-H. Tao, Y. Guo, Y.-H. Joo, B. Twamley and M. S. Jean'ne, Xiong, S. A. Jenekhe, Z. Bao and Y. Xia, Nano lett., 2007, 7,
J. Mater. Chem., 2008, 18, 5524-5530. 2847-2853.
223. T. M. Klapötke, F. A. Martin and J. Stierstorfer, Angew. 250. J. M. Custodio, R. R. Ternavisk, C. J. Ferreira, A. S.
Chem. Int. Ed., 2011, 50, 4227-4229. Figueredo, G. L. Aquino, H. B. Napolitano, C. Valverde and
224. K. Banert, S. Richter, D. Schaarschmidt and H. Lang, Angew. B. Baseia, J. Phys. Chem. A, 2018, 123, 153-162.
Chem. Int. Ed., 2013, 52, 3499-3502. 251. R. Centore, B. Panunzi, A. Roviello, A. Sirigu and P. Villano,
225. B. Wu, H. Yang, Q. Lin, Z. Wang, C. Lu and G. Cheng, New J. Mol. Cryst. Liq. Cryst., 1996, 275, 107-120.
Chem., 2015, 39, 179-186. 252. R. Glaser and G. S. Chen, J. Comput. Chem., 1998, 19, 1130-
226. K. Tiwari, S. Kumar, V. Kumar, J. Kaur, S. Arora and R. K. 1140.
Mahajan, Spectrochim. Acta, Part A, 2018, 191, 16-26. 253. M. Moreno-Mañas, R. Pleixats, R. Andreu, J. Garín, J.
227. T. Wei, G. Liang, X. Chen, J. Qi, Q. Lin, Y. Zhang and H. Yao, Orduna, B. Villacampa, E. Levillain and M. Sallé, J. Mater.
Tetrahedron, 2017, 73, 2938-2942. Chem., 2001, 11, 374-380.
228. D. B. Christopher Leslee, S. Karuppannan, K. M. Vengaian, 254. A. Facchetti, A. Abbotto, L. Beverina, M. E. van der Boom,
S. Gandhi and S. Subramanian, Luminescence, 2017, 32, P. Dutta, G. Evmenenko, T. J. Marks and G. A. Pagani, Chem.
1354-1360. Mater., 2002, 14, 4996-5005.
229. X. Ma, J. Cheng, J. Liu, X. Zhou and H. Xiang, New J. Chem., 255. R. Dworczak, W. M. Fabian, C. Reidlinger, A. Rumpler, J.
2015, 39, 492-500. Schachner and K. Zangger, Spectrochim. Acta, Part A, 2002,
230. Y. Liao, Q. Li, Y. Yue and S. Shao, RSC Adv., 2015, 5, 3232- 58, 2135-2144.
3238. 256. A. Faccinetto, S. Mazzucato, D. Pedron, R. Bozio, S. Destri
231. P. Molina, A. Tárraga and A. Caballero, Eur. J. Inorg. Chem., and W. Porzio, ChemPhysChem, 2008, 9, 2028-2034.
2008, 2008, 3401-3417. 257. B. Vercelli, M. Pasini, A. Berlin, J. Casado, J. T. López
232. A. Caballero, R. Martínez, V. Lloveras, I. Ratera, J. Vidal- Navarrete, R. P. Ortiz and G. Zotti, J. Phys. Chem. C, 2014,
Gancedo, K. Wurst, A. Tárraga, P. Molina and J. Veciana, J. 118, 3984-3993.
Am. Chem. Soc., 2005, 127, 15666-15667. 258. R. Arulmani and K. Sankaran, Spectrochim. Acta,
233. R. Martínez, A. Espinosa, A. Tárraga and P. Molina, Org. Part A, 2014, 129, 491-498.
Lett., 2005, 7, 5869-5872. 259. A. Jarczyk-Jedryka, K. Bijak, D. Sek, M. Siwy, M. Filapek, G.
234. R. Sheng, P. Wang, W. Liu, X. Wu and S. Wu, Sensors Malecki, S. Kula, G. Lewinska, E. M. Nowak and J. Sanetra,
Actuators B: Chem., 2008, 128, 507-511. Opt. Mater., 2015, 39, 58-68.
235. M. Suresh, A. K. Mandal, S. Saha, E. Suresh, A. Mandoli, R. 260. M. K. Poduval, I. Arrechea-Marcos, M. C. R. Delgado, T.
D. Liddo, P. P. Parnigotto, A. Das, Org. Lett., 2010, 12, 5406- Park, J. T. L. Navarrete, R. P. Ortiz and T.-H. Kim, RSC Adv.,
5409. 2016, 6, 44272-44278.
236. S. Dalapati, B. K. Paul, S. Jana and N. Guchhait, Sensors 261. X. Wang, D. Wang, H. Gao, Z. Yang, H. Cao, H. Yang, W. He,
Actuators B: Chem., 2011, 157, 615-620. H. Wang, J. Gu and H. Hu, J. Nonlinear Opt. Phys. Mater.,
237. I. Isa, S. Mustafar, M. Ahmad, N. Hashim and S. Ghani, 2016, 25, 1650014.
Talanta, 2011, 87, 230-234. 262. R. Glaser, N. Knotts, P. Yu, L. Li, M. Chandrasekhar, C.
238. N. Narayanaswamy and T. Govindaraju, Sens. Actuators B: Martin and C. L. Barnes, Dalton Trans., 2006, 2891-2899.
Chem., 2012, 161, 304-310. 263. W. Hong, C. Guo, B. Sun and Y. Li, J. Mater. Chem. C, 2015,
239. D. Ray, S. Dalapati and N. Guchhait, Spectrochim. Acta, 3, 4464-4470.
Part A, 2013, 115, 219-226.
34 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 35